JMP Securities Reiterates “Market Outperform” Rating for Jasper Therapeutics (NASDAQ:JSPR)

JMP Securities reissued their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report report published on Friday, Benzinga reports. They currently have a $70.00 price target on the stock.

JSPR has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an outperform rating for the company in a research report on Wednesday, August 14th. Evercore ISI reiterated an outperform rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Monday, August 26th. Cantor Fitzgerald reiterated an overweight rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Finally, BTIG Research began coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They issued a buy rating and a $90.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $73.00.

Jasper Therapeutics Price Performance

NASDAQ JSPR opened at $18.83 on Friday. The company has a market capitalization of $283.66 million, a PE ratio of -3.34 and a beta of 2.22. The company has a fifty day moving average of $19.66 and a 200 day moving average of $22.45. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. Research analysts expect that Jasper Therapeutics will post -4.16 earnings per share for the current year.

Institutional Trading of Jasper Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JSPR. Opaleye Management Inc. purchased a new stake in Jasper Therapeutics during the 4th quarter valued at about $3,144,000. Kingdon Capital Management L.L.C. grew its stake in Jasper Therapeutics by 16.4% during the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares in the last quarter. StemPoint Capital LP purchased a new stake in Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Ikarian Capital LLC purchased a new stake in Jasper Therapeutics during the 1st quarter valued at about $3,088,000. Finally, Russell Investments Group Ltd. purchased a new stake in Jasper Therapeutics during the 1st quarter valued at about $2,343,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.